This study, called IRONMAN, is creating a large international registry (a collection of health information) for at least 5,000 men with advanced prostate cancer. It includes men with metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic or non-metastatic castration-resistant prostate cancer (M0/M1 CRPC). The goal is to understand how prostate cancer is treated in different places and how those treatments affect patients over time. You would receive standard of care drugs for your prostate cancer, as determined by your local doctor. To join, you must be a man at least 21 years old with a confirmed diagnosis of prostate adenocarcinoma and be willing to provide consent for your health information to be used. The study is currently ongoing, but the exact status is unclear.

Study design

This is an observational study, meaning researchers will collect information about your standard prostate cancer care. It aims to include at least 5,000 men.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The study will track practice patterns for 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.